NCT00291005View on ClinicalTrials.gov

PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone

PHASE2CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

August 31, 2004

Conditions

Prostatic Neoplasms

Interventions

DRUG

ARD6562, Docetaxel

Trial Locations (1)

Unknown

Sanofi-Aventis, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY